Active and inactive forms of matrix metalloproteinases 2 and 9 in cutaneous melanoma

International Journal of Dermatology

Volumn 53, Issue 5, 2014, Pages 575-580

  Candrea, Elisabeta ^a   Senila, Simona ^a   Tatomir, Corina ^b   Cosgarea, Rodica ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CUTANEOUS MELANOMA; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MELANOCYTIC NEVUS; MELANOMA; PROTEIN EXPRESSION; SKIN CANCER; ZYMOGRAPHY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; SKIN TUMOR;

FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84899487652     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05772.x     Document Type: Article

References (19)

1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012; 62: 118-128.
2. MacKie R, Bray C, Vestey J, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer 2007; 96: 1772-1777.
3. Balch CM, Soong SJ, Gerschenwald JE, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
4. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006; 11: 479-491.
5. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-735.
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 16: 3635-3648.
7. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234.
8. Bradford MM. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
9. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-289.
10. Hofmann UB, Westphal JR, Waas ET, et al. Matrix metalloproteinases in human melanomacelllines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999; 81: 774-782.
11. Hofmann UB, Westphal JR, Zendman AJ, et al. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191: 245-256.
12. Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 2011; 42: 1103-1111.
13. Kim HK, Chae SW, Woo KI, Kim YD. Expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications. Jpn J Ophthalmol 2010; 54: 221-226.
14. Van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-670.
15. Hofmann UB, Eggert AA, Blass K, et al. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003; 63: 8221-8225.
16. Chen Y, Chen Y, Huang L, Yu J. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol 2011; 39: 339-343.
17. Kondratiev S, Gnepp DR, Yakirevich E, et al. Expression and prognostic role of MMP2, MMP9, MMP13 and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanoma. Hum Pathol 2008; 39: 337-343.
18. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 5158-5166.
19. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005; 30: 541-545.